|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Vets_First_Choice
gptkb:Merial
|
|
gptkbp:awards
|
Best Workplaces
Top Employer Europe
|
|
gptkbp:business_model
|
research-driven
|
|
gptkbp:ceo
|
gptkb:Hubertus_von_Baumbach
|
|
gptkbp:clinical_trial
|
ongoing
collaborative efforts
|
|
gptkbp:community_programs
|
animal welfare
health education
disease prevention
|
|
gptkbp:employees
|
approximately 50,000
|
|
gptkbp:founded
|
1885
|
|
gptkbp:founder
|
gptkb:Albert_Boehringer
|
|
gptkbp:global_presence
|
over 150 countries
|
|
gptkbp:headcount
|
over 50,000
|
|
gptkbp:headquarters
|
gptkb:Ingelheim,_Germany
Ingelheim am Rhein, Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Boehringer Ingelheim Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:invention
|
numerous patents
|
|
gptkbp:market
|
global pharmaceutical market
|
|
gptkbp:parent_company
|
gptkb:Boehringer_Ingelheim_Group
|
|
gptkbp:partnership
|
gptkb:Sanofi
gptkb:Pfizer
|
|
gptkbp:philosophy
|
value-driven approach
|
|
gptkbp:products
|
prescription medications
|
|
gptkbp:research_and_development
|
significant investment
|
|
gptkbp:research_areas
|
neurology
oncology
immunology
cardiovascular
respiratory
|
|
gptkbp:research_focus
|
animal health
human pharmaceuticals
|
|
gptkbp:revenue
|
approximately €19 billion
|
|
gptkbp:social_responsibility
|
gptkb:healthcare_access
community engagement
sustainability initiatives
|
|
gptkbp:subsidiaries
|
gptkb:Boehringer_Ingelheim_Animal_Health
gptkb:Boehringer_Ingelheim_Vetmedica
|
|
gptkbp:website
|
www.boehringer-ingelheim.com
|
|
gptkbp:bfsParent
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:bfsLayer
|
4
|